Advertisement

HindustanTimes Thu,28 Aug 2014

EU fines Ranbaxy for blocking cheaper drugs

Reuters  Brussels, June 19, 2013
First Published: 15:27 IST(19/6/2013) | Last Updated: 19:04 IST(19/6/2013)

European Union (EU) antitrust regulators fined nine drugmakers a total of 146 million euros on Wednesday for blocking the supply of cheaper medicines on the market, with a penalty of 94 million euros imposed on Denmark's Lundbeck.

Advertisement

The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said "pay-for-delay" deals lead to consumers paying as much as 20 percent more for their medicines.

The European Commission, which acts as competition regulator across the 27-member European Union, imposed a 21.4 million euro fine on Germany's Merck KGaA and another 7.77 million euros on it jointly with former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.

The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, A.L. Industrier and India's No. 1 pharmaceutical company Ranbaxy.

Reuters flagged the EU fines on June 3.

"Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints," EU Competition Commissioner Joaquin Almunia said in a statement.

"The Commission will not tolerate such anticompetitive practices."


Advertisement
more from Business

Not flying high: Air India faces maximum passenger complaints

Air India tops the list of passenger complaints lodged against Indian airlines in July this year, followed by no-frill carrier SpiceJet, official data shows. Most air travellers, who have lodged complaints against the airlines, complained of problems relating to delayed flights and their customer services.

markets
Advertisement
Most Popular
Advertisement
Advertisement
Copyright © 2014 HT Media Limited. All Rights Reserved